This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Juarez, J. C. Articles by Doñate, F. Search for Related Content PubMed PubMed Citation Articles by Juarez, J. C. Articles by Doñate, F.

Histidine-Proline-rich Glycoprotein Has Potent Antiangiogenic Activity Mediated through the Histidine-Proline-rich Domain¹

Attenuon, LLC, San Diego, California 92121 [J. C. J., X. G, M. L. P., G. C.P., D. E. S., A. P. M., F. D.]; Division of Molecular Biology and Biochemistry, School of Biological Sciences, University of Missouri-Kansas City, Kansas City, Missouri 64110 [N. V. S., W. T. M.]; McGill University Health Center [S. A. R.] and Division of Hematology-Oncology [J-C. Z., K. R. M.], Case Western Reserve University, School of Medicine, Ohio 44106

Histidine-proline-rich glycoprotein (HPRG) is an abundant multidomain plasma protein evolutionarily related to high-molecular-weight kininogen. The cleaved form of high-molecular-weight kininogen has recently been demonstrated to exhibit antiangiogenic activities in vitro (J. C. Zhang et al., FASEB J., 14: 2589–2600, 2000), mediated primarily through domain 5. HPRG contains a histidine-proline-rich (H/P) domain with sequence and functional similarities to HKa-D5. We hypothesized that HPRG may also have antiangiogenic properties, localized within its H/P domain. The H/P domain is highly conserved among species, and because rabbit H/P domain is more resistant to internal proteolytic cleavage than the human domain, the rabbit HPRG (rbHPRG) was primarily used to assess the antiangiogenic activity of HPRG. Rabbit HPRG inhibited human umbilical vein endothelial cell (HUVEC) tube formation stimulated by fibroblast growth factor-2 (FGF-2) or vascular endothelial growth factor on a Matrigel surface as well as cell proliferation of FGF-2 stimulated HUVECs. The antiangiogenic activity of rbHPRG was localized to the H/P domain by use of proteolytic fragments of rbHPRG and was further confirmed and characterized in two in vivo models of angiogenesis: the chorioallantoic membrane of the chick assay and the mouse Matrigel plug assay. Caspase-3 activation was observed in HUVECs stimulated with FGF-2 in the presence of rbHPRG, suggesting that apoptosis of activated endothelial cells may be one of the mechanisms underlying its antiangiogenic activity. Finally, the H/P domain of rbHPRG reduced tumor cell number when tumor cells were co-inoculated in the Matrigel plug assay. In conclusion, the H/P domain within HPRG induces the apoptosis of activated endothelial cells leading to potent antiangiogenic effects.

This article has been cited by other articles:

				S. Wang, W.-M. Yu, W. Zhang, K. R. McCrae, B. G. Neel, and C.-K. Qu Noonan Syndrome/Leukemia-associated Gain-of-function Mutations in SHP-2 Phosphatase (PTPN11) Enhance Cell Migration and Angiogenesis J. Biol. Chem., January 9, 2009; 284(2): 913 - 920. [Abstract] [Full Text] [PDF]

				T. Sakai, K. Balasubramanian, S. Maiti, J. B. Halder, and A. J. Schroit Plasmin-Cleaved {beta}-2-Glycoprotein 1 Is an Inhibitor of Angiogenesis Am. J. Pathol., November 1, 2007; 171(5): 1659 - 1669. [Abstract] [Full Text] [PDF]

				C. S. Boosani, A. P. Mannam, D. Cosgrove, R. Silva, K. M. Hodivala-Dilke, V. G. Keshamouni, and A. Sudhakar Regulation of COX-2 mediated signaling by {alpha}3 type IV noncollagenous domain in tumor angiogenesis Blood, August 15, 2007; 110(4): 1168 - 1177. [Abstract] [Full Text] [PDF]

				E. S. Yao, H. Zhang, Y.-Y. Chen, B. Lee, K. Chew, D. Moore, and C. Park Increased {beta}1 Integrin Is Associated with Decreased Survival in Invasive Breast Cancer Cancer Res., January 15, 2007; 67(2): 659 - 664. [Abstract] [Full Text] [PDF]

				N. Pore, A. K. Gupta, G. J. Cerniglia, Z. Jiang, E. J. Bernhard, S. M. Evans, C. J. Koch, S. M. Hahn, and A. Maity Nelfinavir Down-regulates Hypoxia-Inducible Factor 1{alpha} and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy. Cancer Res., September 15, 2006; 66(18): 9252 - 9259. [Abstract] [Full Text] [PDF]

				M. Vanwildemeersch, A.-K. Olsson, E. Gottfridsson, L. Claesson-Welsh, U. Lindahl, and D. Spillmann The Anti-angiogenic His/Pro-rich Fragment of Histidine-rich Glycoprotein Binds to Endothelial Cell Heparan Sulfate in a Zn2+-dependent Manner J. Biol. Chem., April 14, 2006; 281(15): 10298 - 10304. [Abstract] [Full Text] [PDF]

				J. Dixelius, A.-K. Olsson, A. Thulin, C. Lee, I. Johansson, and L. Claesson-Welsh Minimal Active Domain and Mechanism of Action of the Angiogenesis Inhibitor Histidine-Rich Glycoprotein Cancer Res., February 15, 2006; 66(4): 2089 - 2097. [Abstract] [Full Text] [PDF]

				A. L. Jones, I. K. H. Poon, M. D. Hulett, and C. R. Parish Histidine-rich Glycoprotein Specifically Binds to Necrotic Cells via Its Amino-terminal Domain and Facilitates Necrotic Cell Phagocytosis J. Biol. Chem., October 21, 2005; 280(42): 35733 - 35741. [Abstract] [Full Text] [PDF]

				J.-L. Su, K.-P. Lai, C.-A. Chen, C.-Y. Yang, P.-S. Chen, C.-C. Chang, C.-H. Chou, C.-L. Hu, M.-L. Kuo, C.-Y. Hsieh, et al. A Novel Peptide Specifically Binding to Interleukin-6 Receptor (gp80) Inhibits Angiogenesis and Tumor Growth Cancer Res., June 1, 2005; 65(11): 4827 - 4835. [Abstract] [Full Text] [PDF]

				N. Pore, S. Liu, H.-K. Shu, B. Li, D. Haas-Kogan, D. Stokoe, J. Milanini-Mongiat, G. Pages, D. M. O'Rourke, E. Bernhard, et al. Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1-independent Mechanism Mol. Biol. Cell, November 1, 2004; 15(11): 4841 - 4853. [Abstract] [Full Text] [PDF]

				M. F. B. G. Gebbink, E. E. Voest, and A. Reijerkerk Do antiangiogenic protein fragments have amyloid properties? Blood, September 15, 2004; 104(6): 1601 - 1605. [Abstract] [Full Text] [PDF]

				F. Donate, J. C. Juarez, X. Guan, N. V. Shipulina, M. L. Plunkett, Z. Tel-Tsur, D. E. Shaw, W. T. Morgan, and A. P. Mazar Peptides Derived from the Histidine-Proline Domain of the Histidine-Proline-Rich Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities Cancer Res., August 15, 2004; 64(16): 5812 - 5817. [Abstract] [Full Text] [PDF]

				A.-K. Olsson, H. Larsson, J. Dixelius, I. Johansson, C. Lee, C. Oellig, I. Bjork, and L. Claesson-Welsh A Fragment of Histidine-Rich Glycoprotein Is a Potent Inhibitor of Tumor Vascularization Cancer Res., January 15, 2004; 64(2): 599 - 605. [Abstract] [Full Text] [PDF]

				H. Maekawa, Y. Oike, S. Kanda, Y. Ito, Y. Yamada, H. Kurihara, R. Nagai, and T. Suda Ephrin-B2 Induces Migration of Endothelial Cells Through the Phosphatidylinositol-3 Kinase Pathway and Promotes Angiogenesis in Adult Vasculature Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2008 - 2014. [Abstract] [Full Text] [PDF]